Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of CAI (Carboxyamidotriazole) and glutamate uptake and metabolic inhibitors in resisting tumor

A metabolic inhibitor, carboxyaminotriazole technology, applied in the application field of carboxyamidotriazole and glutamic acid uptake and metabolism inhibitors in anti-tumor, can solve the problems of high toxicity and difficult application, and achieve non-toxic Side effects, high safety, effect of blocking energy supply

Active Publication Date: 2019-04-26
GUANGDONG YINZHU PHARMACEUTICAL TECHNOLOGY CO LTD
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Since the energy supply of normal cells in the body is highly dependent on glucose metabolism and fatty acid metabolism, drugs developed for the targets of carbohydrate and fatty acid metabolism in tumor cells are highly toxic to normal cells in the body and are difficult to apply clinically

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of CAI (Carboxyamidotriazole) and glutamate uptake and metabolic inhibitors in resisting tumor
  • Application of CAI (Carboxyamidotriazole) and glutamate uptake and metabolic inhibitors in resisting tumor
  • Application of CAI (Carboxyamidotriazole) and glutamate uptake and metabolic inhibitors in resisting tumor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0052] Example 1: Carboxytriazole reduces the sugar utilization rate of tumor cells.

[0053] 1. Experimental method

[0054] After the cells were treated with CAI (10 μM) for 48 hours, the levels of oxidative phosphorylation OCR and glycolytic ECAR of these cells were detected using a seahorse energy metabolism detector.

[0055] 2. Experimental results

[0056] As shown in Figure 1, the results of Seahorse showed that in the case of CAI administration, both OCR and ECAR were reduced, and the reduction of OCR could not be stimulated by the uncoupler FCCP. Similarly, the detection of ECAR in the administration group was added Oligomycin, an inhibitor of oxidative phosphorylation, also did not reverse the drug-induced decrease.

Embodiment 2

[0057] Example 2: Carboxytriazole increases phosphorylated ACC.

[0058] 1. Experimental method

[0059] After the cells were incubated with 5, 10, and 20 μM CAI for 48 hours, protein samples were collected. For protein quantification, the loading amount of 40 μg per well was detected by Western blot electrophoresis to detect the expression level of phosphorylated ACC.

[0060] 2. Experimental results

[0061] Such as figure 2 As shown, the expression of phosphorylated ACC increased with the concentration of CAI.

Embodiment 3

[0062] Example 3. Increased utilization of amino acids in tumor cells after the action of carboxytriazole.

[0063] 1. Experimental method

[0064] After the cells were treated with CAI (10 μM) for 48 hours, the changes in the intake ratios of the three energy sources of glycolipids and amino acids in these cells after administration were detected by using a seahorse energy metabolism detector.

[0065] 2. Experimental results

[0066] Such as image 3 As shown, Seahorse's results showed that in the case of CAI administration, the main source of energy capacitation of cells was more inclined to utilize amino acid production capacity.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of CAI (Carboxyamidotriazole) and glutamate uptake and metabolic inhibitors in resisting tumor. Specifically, the invention relates to the application of the CAI and a combination of one or multiple glutamate uptake and metabolic inhibitors in preparing an anti-tumor drug for mammals. Particularly, the invention relates to the application of the CAI and a combination of an amino acid transporter inhibitor, a glutamate dehydrogenase 1 inhibitor and a glutaminase inhibitor in preparing the anti-tumor drug for the mammals.

Description

technical field [0001] The present invention relates to the field of medical treatment and medicine, in particular to the treatment of malignant tumors and the anti-cancer drugs through the method of combination drug, in particular to carboxylamine triazole and its derivatives and amino acid transporter inhibitors, GDH1 inhibitors or GLS inhibitors , a method for synergistically controlling the energy utilization of tumor cells, and treating malignant tumors, and a combination of anti-tumor drug preparations. Background technique [0002] Any life activity is inseparable from the corresponding material and energy basis. For tumor cells, they must not only proliferate rapidly, but also find ways to escape immune surveillance, and under certain circumstances, they must also transfer to other parts of the body. While resisting drug attacks, they must also find ways to make a comeback. Metabolic disorder is one of the typical characteristics of malignant tumors and is closely r...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/4192A61K31/198A61P35/00
CPCA61K31/198A61K31/4192A61P35/00A61K2300/00
Inventor 郭磊张德昌叶菜英石婧
Owner GUANGDONG YINZHU PHARMACEUTICAL TECHNOLOGY CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com